Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Palisade Bio (PALI) EBITDA Margin (2016 - 2023)

Palisade Bio has reported EBITDA Margin over the past 11 years, most recently at 1011.6% for Q1 2023.

  • Quarterly EBITDA Margin changed N/A to 1011.6% in Q1 2023 from the year-ago period, while the trailing twelve-month figure was 5228.0% through Dec 2023, changed N/A year-over-year, with the annual reading at 5228.0% for FY2023, N/A changed from the prior year.
  • EBITDA Margin was 1011.6% for Q1 2023 at Palisade Bio, up from 176623.48% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 1011.6% in Q1 2023 and troughed at 176623.48% in Q4 2020.
  • The 3-year median for EBITDA Margin is 81444.8% (2019), against an average of 85473.82%.
  • Year-over-year, EBITDA Margin soared 252640bps in 2019 and then crashed -9517868bps in 2020.
  • A 3-year view of EBITDA Margin shows it stood at 81444.8% in 2019, then plummeted by -117bps to 176623.48% in 2020, then surged by 99bps to 1011.6% in 2023.
  • Per Business Quant, the three most recent readings for PALI's EBITDA Margin are 1011.6% (Q1 2023), 176623.48% (Q4 2020), and 92745.68% (Q3 2020).